<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282137</url>
  </required_header>
  <id_info>
    <org_study_id>Ga PSMA124388</org_study_id>
    <secondary_id>IND124388</secondary_id>
    <nct_id>NCT02282137</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer</brief_title>
  <acronym>PSMA</acronym>
  <official_title>68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ebrahim Delpassand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiomedix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Excel Diagnostics and Nuclear Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radio Isotope Therapy of America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II clinical trial study to show how well the 68Ga-PSMA-11 (ProstaMedix™)&#xD;
      PET-CT scan works in detecting tumor location and size in patients with suspected or&#xD;
      confirmed prostate cancer, as well as prostate cancer that may have come back in patients&#xD;
      with elevated PSA ( a prostate-specific antigen tumor marker) after initial treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      68Ga-PSMA-11 is a radioactive imaging contrast agent for use in PET CT scan that seeks to&#xD;
      identify prostate cancer cells that have a specific protein target called prostate-specific&#xD;
      membrane antigen (PSMA) on their surface. PET and CT make computerizing pictures of areas&#xD;
      inside the body where the radioactive substance is lighting up. 68Ga-PSMA-11 PET / CT may be&#xD;
      able to see smaller tumors than standard imaging and may help determine whether prostate&#xD;
      cancer has come back and where it is in the body.&#xD;
&#xD;
      A 68Ga-PSMA-11 PET / CT scan may help doctors to better detect the location, extent, and&#xD;
      characteristics of the tumor, allowing improved planning of subsequent therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sensitivity of 68Ga-PSMA-11 PET for detection of tumor location.</measure>
    <time_frame>12 months</time_frame>
    <description>The sensitivity of 68Ga-PSMA-11 PET to detect tumor location and metastases in patients with biopsy confirmed diagnosis.tumor location confirmed by histopathology/biopsy and conventional imaging follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rates of 68Ga-PSMA-11 PET in patients with different PSA value</measure>
    <time_frame>12 months</time_frame>
    <description>Detection rates of 68Ga-PSMA-11 PET in patients with different PSA value (0.2 - &lt;0.5, 0.5 - &lt;1.0, 1.0 - &lt;2.0, 2.0 - &lt;5.0, 5.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA</intervention_name>
    <description>Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.</description>
    <arm_group_label>68Ga-PSMA</arm_group_label>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        General requirements:&#xD;
&#xD;
          1. Karnofsky performance status of ≥50 (or ECOG/WHO equivalent).&#xD;
&#xD;
          2. Age &gt; 18 years .&#xD;
&#xD;
          3. Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it.&#xD;
&#xD;
          4. i. inclusion criteria specific for the pre-prostatectomy group:&#xD;
&#xD;
               -  Biopsy proven prostate adenocarcinoma.&#xD;
&#xD;
               -  Planned prostatectomy with lymph node dissection.&#xD;
&#xD;
               -  Intermediate to high-risk disease (as determined by elevated PSA [PSA&gt;10],&#xD;
                  T-stage [T2b or greater], Gleason score [Gleason score &gt; 6] or other risk&#xD;
                  factors).&#xD;
&#xD;
        4. ii. inclusion criteria specific for biochemical recurrence group:&#xD;
&#xD;
          -  Histopathological proven prostate adenocarcinoma.&#xD;
&#xD;
          -  Rising PSA after definitive therapy with prostatectomy or radiation therapy (external&#xD;
             beam or brachytherapy).&#xD;
&#xD;
               1. Post radical prostatectomy (RP) - AUA recommendation, PSA greater than or equal&#xD;
                  to 0.2 ng/mL measured more than 6 weeks after RP.&#xD;
&#xD;
               2. Post-radiation therapy -ASTRO-Phoenix consensus definition, Nadir + greater than&#xD;
                  or equal to 2 ng/mL rise in PSA 5. Diagnostic CT or MRI as part of the PET study&#xD;
                  or performed within one month of PSMA PET&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        General requirements:&#xD;
&#xD;
          1. Patients not capable of getting PET study due to weight, claustrophobia, or inability&#xD;
             to lay still for the duration of the exam.&#xD;
&#xD;
          2. Contraindication to furosemide administration including prior allergy or adverse&#xD;
             reaction to furosemide or sulfa drugs. (Note: This exclusion criterion can be removed&#xD;
             if Furosemide is omitted as part of the PET imaging protocol if a second-generation&#xD;
             scatter correction is available for the used PET device).&#xD;
&#xD;
          3. i. Exclusion criteria specific for the pre-prostatectomy group: Neoadjuvant&#xD;
             chemotherapy or radiation therapy prior to prostatectomy, including focal ablation&#xD;
             techniques (HiFu) within the last 2 months.&#xD;
&#xD;
        3. ii. Exclusion criteria specific for biochemical recurrence group:&#xD;
&#xD;
          -  Investigational therapy for prostate cancer for less than 2 months.&#xD;
&#xD;
          -  Prior history of any other malignancy within the last 2 years, other than skin basal&#xD;
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and&#xD;
             superficial bladder cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Nunez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excel Diagnostics and Nuclear Oncology Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Cork</last_name>
    <phone>713-781-6200</phone>
    <phone_ext>3203</phone_ext>
    <email>Scork@exceldiagnostics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodolfo Nunez, MD</last_name>
    <phone>713-781-6200</phone>
    <phone_ext>3225</phone_ext>
    <email>Rnunez@exceldiagnostics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radio- Isotope Therapy of America</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cork</last_name>
      <phone>713-341-3203</phone>
      <email>scork@exceldiagnostics.com</email>
    </contact>
    <contact_backup>
      <last_name>Ayman Gaber, MBBCh-MS</last_name>
      <phone>713-781-6200</phone>
      <phone_ext>3242</phone_ext>
      <email>agaber@exceldiagnostics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rodolfo Nunez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ebrahim S Delpassand, MD-FACNM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman Gaber, MBBCh-MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Radio Isotope Therapy of America</investigator_affiliation>
    <investigator_full_name>Ebrahim Delpassand</investigator_full_name>
    <investigator_title>Chairman and Medical Director</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>PET / CT</keyword>
  <keyword>Ga-PSMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

